Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
米国において認知症に関する臨床研究を牽引してきたのはADCS(Alzheimer's Disease Cooperative Study)であるが,2015年に所長のPaul Aisen博士をはじめADCSの主要なメンバーが南カリフォルニア大学ケック医学校に移籍してATRI(Alzheimer's Therapeutic Research Institute)が設立された。2017年度NIH(National Institute of Health)はATRIに対してACTC(Alzheimer's Clinical Trials Consortium)プロジェクトを用意して支援を行う予定である。世界的に有名な研究であるA4研究や,ADNI研究もATRIに移っている。ATRIではデータ共有が進んでおり,また独立したモニタリング組織も有している。米国での今後の認知症臨床研究はこのATRIが中心になると思われる。
Abstract
The Alzheimer's Therapeutic Research Institute (ATRI) was established in 2015 after ATRI director, Paul Aisen, and his fellow experts in therapeutic interventions for Alzheimer's disease (AD) moved from the Alzheimer's Disease Cooperative Study (ADCS) at the University of California to the Keck School of Medicine of the University of Southern California. The National Institute on Aging (NIA) decided to commit $14 million to the ATRI via an Alzheimer's Clinical Trials Consortium (ACTC). The ATRI supports various studies such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer's study ("A4 study"), Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3), Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN), and The Alzheimer's Disease Neuroimaging Initiative-Depression Project (ADNI-D). The ATRI will share all relevant data and materials with the academic community, corporations, and government organizations. The ATRI is overseen by a Data and Safety Monitoring Board (DSMB), which comprises of leading experts in the field of Alzheimer's research and acts independently. The ATRI is slated to play a central role in clinical dementia research in the US in near future.
Copyright © 2017, Igaku-Shoin Ltd. All rights reserved.